Hanmi Science Co., Ltd.

KSE 008930.KS

Hanmi Science Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 604.81 M

Hanmi Science Co., Ltd. Shareholders' Equity is USD 604.81 M for the year ending December 31, 2023, a 5.63% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Hanmi Science Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 572.55 M, a -0.91% change year over year.
  • Hanmi Science Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 577.78 M, a -4.45% change year over year.
  • Hanmi Science Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 604.72 M, a 8.65% change year over year.
  • Hanmi Science Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 556.58 M, a -4.67% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
SV Wall Street
KSE: 008930.KS

Hanmi Science Co., Ltd.

CEO Mr. Jong-Hoon Lim
IPO Date Sept. 29, 2005
Location South Korea
Headquarters 14, Wiryeseong-daero
Employees 402
Sector Healthcare
Industries
Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care
Description

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.

StockViz Staff

February 4, 2025

Any question? Send us an email